Related Experiment Video
Updated: Oct 25, 2025
08:18
Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
3.5K
Biopharmaceutical Study on Nobiletin-Loaded Amorphous Solid Dispersion with Improved Hypouricemic Effect.
Takuya Nihei1, Eri Ushiro1, Hideyuki Sato1
1Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Molecules (Basel, Switzerland)
|August 7, 2021
Summary
This study developed amorphous solid dispersion of nobiletin (ASD/NOB) using hydroxypropyl cellulose-SSL. ASD/NOB significantly improved nobiletin
Area of Science:
- Pharmacology and Pharmaceutics
- Drug Delivery Systems
- Natural Product Chemistry
Background:
- Nobiletin (NOB) is a flavonoid with potential therapeutic benefits but limited bioavailability.
- Improving NOB's pharmacokinetic profile is crucial for enhancing its therapeutic efficacy.
- Hyperuricemia is a condition associated with elevated uric acid levels, increasing the risk of gout and other health issues.
Purpose of the Study:
- To develop an amorphous solid dispersion of nobiletin (ASD/NOB) using hydroxypropyl cellulose-SSL (HPC-SSL).
- To enhance the dissolution, pharmacokinetic properties, and hypouricemic effect of nobiletin.
- To evaluate ASD/NOB as a potential nutraceutical option for managing hyperuricemia.
Main Methods:
- Amorphous solid dispersion of nobiletin (ASD/NOB) was prepared using the freeze-drying method with HPC-SSL.
- Characterization included assessment of crystallinity, dissolution profiles, and pharmacokinetic behavior in rats.
- The hypouricemic effect was evaluated in a rat model of hyperuricemia.
Main Results:
- ASD/NOB exhibited a 4.4-fold increase in dissolved nobiletin concentration compared to crystalline NOB at 2 hours.
- Oral administration of ASD/NOB resulted in an 18-fold enhancement in oral bioavailability and a 60% reduction in Tmax.
- ASD/NOB demonstrated a 16% greater reduction in plasma uric acid levels in hyperuricemic rats compared to crystalline NOB.
Conclusions:
- Freeze-dried ASD/NOB significantly enhances nobiletin's dissolution and oral bioavailability.
- ASD/NOB shows improved pharmacokinetic properties and a notable hypouricemic effect in vivo.
- ASD/NOB represents a promising dosage form for improving the nutraceutical potential of nobiletin in hyperuricemia management.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
30
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
30
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
34
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
34
01:16Bioavailability Enhancement: Drug Solubility Enhancement
28
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
28
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.1K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.1K
01:13Bioequivalence studies: Biowaivers
37
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
37
01:17In Vitro Drug Dissolution: Alternative Methods
37
Alternative drug dissolution methods include the rotating bottle, intrinsic dissolution test, peristalsis, and the Franz diffusion cell method. The rotating bottle method involves meticulously rotating tightly capped controlled-release beads in a temperature-controlled bath. Periodic decanting of samples allows for residue assay, followed by refilling with fresh medium and testing at various pH levels to emulate the gastrointestinal tract conditions.In contrast, the intrinsic dissolution test...
37